Literature DB >> 8683260

Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia.

M B Marinov1, K S Harbaugh, P J Hoopes, H J Pikus, R E Harbaugh.   

Abstract

The known cytoprotective properties of MgSO4 led the authors to study its effects on infarct size in rats when administered intraarterially before reversible focal ischemia. Following an intracarotid infusion of MgSO4 in the amount of 30 mg/kg (24 animals), 90 mg/kg (18 animals), or an equal volume of vehicle (23 animals), middle cerebral artery occlusion was produced in rats by means of an intraluminal suture technique. Reperfusion occurred after 1.5 (42 animals) or 2 hours (23 animals) of ischemia. Automated, volumetric measurements of 2',3',5'-triphenyl-2H-tetrazolium chloride-stained coronal brain sections demonstrated a statistically significant decrease in infarct size for MgSO4 treatment groups compared to controls. Cytoprotection was greater in animals subjected to 1.5 hours of ischemia (28.4% reduction in infarct volume, p < 0.001, Student's t-test), than in those having 2 hours of ischemia (19.3% reduction, p < 0.05). Animals given 90 mg/kg MgSO4 prior to 1.5 hours of ischemia (12 animals) showed a 59.8% reduction in infarct volume compared to controls (11 animals, p < 0.001) and a 43.1% reduction compared to the 30 mg/kg group (11 animals, p < 0.001). Analysis of variance demonstrated the statistically significant effects of MgSO4 doses on infarct volume across all groups (F = 22.95, p < 0.0001). The neuroprotective effect of intraarterial MgSO4 in this model is robust, dose dependent, and related to the duration of ischemia. The compound may be valuable for limiting infarction if given intraarterially before induction of reversible ischemia during cerebrovascular surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683260     DOI: 10.3171/jns.1996.85.1.0117

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  34 in total

Review 1.  Magnesium neuroprotection is limited in humans with acute brain injury.

Authors:  J Andrew McKee; Randall P Brewer; Gary E Macy; Cecil O Borel; James D Reynolds; David S Warner
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 2.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

3.  Neuroprotection after major cardiovascular surgery.

Authors:  Jose Torres; Koto Ishida
Journal:  Curr Treat Options Neurol       Date:  2015-07       Impact factor: 3.598

Review 4.  Treatment options for cerebral vasospasm in aneurysmal subarachnoid hemorrhage.

Authors:  M Kamran Athar; Joshua M Levine
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 5.  Intra-arterial neuroprotective therapy as an adjunct to endovascular intervention in acute ischemic stroke: A review of the literature and future directions.

Authors:  Thomas W Link; Alejandro Santillan; Athos Patsalides
Journal:  Interv Neuroradiol       Date:  2020-05-19       Impact factor: 1.610

6.  Magnesium Sulfate Provides Neuroprotection in Eclampsia-Like Seizure Model by Ameliorating Neuroinflammation and Brain Edema.

Authors:  Xiaolan Li; Xinjia Han; Jinying Yang; Junjie Bao; Xiaodan Di; Guozheng Zhang; Huishu Liu
Journal:  Mol Neurobiol       Date:  2016-11-22       Impact factor: 5.590

7.  Serum magnesium levels as related to symptomatic vasospasm and outcome following aneurysmal subarachnoid hemorrhage.

Authors:  Frederic P Collignon; Jonathan A Friedman; David G Piepgras; Mark A Pichelmann; Jon I McIver; L Gerard Toussaint; Robyn L McClelland
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

Review 8.  Magnesium sulfate administration in subarachnoid hemorrhage.

Authors:  Jose I Suarez
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 9.  Magnesium for neuroprotection in ischaemic stroke: rationale for use and evidence of effectiveness.

Authors:  K W Muir
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

10.  Results of the MRI substudy of the intravenous magnesium efficacy in stroke trial.

Authors:  Chelsea S Kidwell; Kennedy R Lees; Keith W Muir; Christopher Chen; Stephen M Davis; Deidre A De Silva; Christopher J Weir; Sidney Starkman; Jeffry R Alger; Jeffrey L Saver
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.